CUDC-907 boosts temozolomide response in glioblastoma by dual PI3K/HDAC inhibition
Glioblastoma (GBM) is an aggressive brain cancer that frequently returns after treatment, largely due to acquired resistance to standard chemotherapy such as temozolomide (TMZ). In...















